Archive for month: August, 2020

GAMBICA at Medica

, /in /by

GAMBICA is the Trade Association for Instrumentation, Control, Automation and Laboratory Technology in the UK. Our insight and influence help our members to be more competitive by increasing their knowledge and impact. Together we remove barriers and maximise the market potential in our industry.
GAMBICA members are active in the following sectors:
•    Industrial automation products and systems
•    Process instrumentation and control
•    Laboratory technology
•    Test and measurement equipment for electrical and electronics industries

www.gambica.org.uk Medica booth # 1G01-3

Starna Scientific at Medica

, /in /by

Starna, established 1964, has a worldwide reputation for quality, service and innovation in the production and supply of spectrophotometer cells, optical components and Certified Reference Materials (CRMs). World-leader with over 50 years’ experience in the production of Certified Reference Materials for UV-Vis-NIR & Fluorescence spectroscopy; it is the only company to achieve both ISO/IEC 17025 and ISO 17034 for this range of products. A highly regarded manufacturer of high precision quartz and glass Cells/Cuvettes for Photometers and Fluorimeters. Starna sells worldwide to instrument manufacturers, pharmaceuti-
cals, life-biosciences, R&D laboratories, medical companies and universities.

www.starna.comBooth # 1G11-2

Jackson ImmunoResearch at Medica

, /in /by

Jackson ImmunoResearch manufactures secondary antibodies and conjugates, with an outstanding reputation for quality, earned over 30 years. Our
products are used in Western Blotting, IHC/ICC/IF, Flow Cytometry, ELISA, Electron Microscopy and many other immunological techniques. From our UK office we serve Europe with euro pricing, technical service and fast delivery.www.jacksonimmuno.com Booth # 1F03-9

Oncimmune at Medica

, /in /by

The battle against cancer hinges on the early detection and then delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease-detecting capabilities of the immune system to find cancer in its early stages. Oncimmune’s range of diagnostic tests assist clinicians to identify the presence of cancer on average four years before standard clinical diag-
nosis, whilst its technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

www.oncimmune.comBooth # 1F03-10

Astell Scientific at Medica

, /in /by

Astell Scientific is a world renowned manufacturer and supplier of steam sterilizers. Astell Scientific autoclaves, steam generators and effluent decontamination systems (EDS) are designed to meet the exacting demands of modern Laboratory, Research and Medical professionals, and as such incorporate innovations such as colour touchscreen controllers as standard throughout the range.

We manufacture:
•    Circular section autoclaves from 30-330 litres
•    Square Section autoclaves from 125 – 2000 litres
•    Steam Generators up to 72 kW
•    Effluent Decontamination Systems (EDS)
•    Customized steam sterilizers to meet the most challenging of applications
All Astell autoclaves are manufactured in accordance with standards and directives including ISO 9001:2015, Pressure Equipment Directive (PED 2014/68/EU) and CE (Conformité Européenne).www.astell.comBooth # 1G11-1

Call for abstracts is now open for the 44th World Hospital Congress in Barcelona (Spain)

, /in /by

The IHF World Hospital Congress is a unique global forum that brings together leaders of hospitals, health services, and healthcare organizations to discuss key drivers of national and international policy, management, financial trends and solutions. The 44th edition of the World Hospital Congress will take place on 2 to 5 November, 2020 at the Palau de Congressos de Catalunya in Barcelona. Professionals from the health sector interested in sharing their work to the international healthcare community are now invited to submit their abstracts.
The International Hospital Federation and La Unió Catalana d’Hospitals, organizers of the congress, invite leaders and professionals from hospitals, health services, and healthcare organizations to submit abstracts for an opportunity to showcase their best practices, innovations, projects, programs and researches to over a thousand peers from around the world.
The congress will tackle the overarching theme “People on board, transforming healthcare”.
“The demands of the society and industry have forced healthcare to transform in ways we wouldn’t have imagined before. And now that transformations are very well in motion, there is so much for us to understand and implement,” said Prof. Antoni Trilla, Chair of the Scientific Committee of the World Hospital Congress.
Those interested to present their work through an oral presentation or as a poster can submit abstracts online under the following sub-themes:
DIGITAL AND TECHNOLOGY DRIVEN TRANSFORMATIONS
· Artificial Intelligence for smart health and care
· Big accurate data: how it helps us
· How is digital health transforming the way health systems are run and healthcare is delivered
· Glocalization: new actors, new rules, global healthcare invaders in the local healthcare set
TOWARDS AN INTEGRATED CONCEPT OF HEALTH AND CARE SERVICES MODEL: VALUE DRIVEN TRANSFORMATIONS
· Enabling the flexibility of organizations to adapt quickly to changes, addressing accelerated innovation adoption
· Key results that really matter: patients outcomes as the driver for better healthcare
· Health and care sustainability supported by applied research and innovation adoption
· Global Healthcare, global mobility, global access: towards a liquid borderless healthcare system
PEOPLE AT THE CENTER OF HEALTHCARE SYSTEM TRANSFORMATIONS
· How to put citizens at the center of health and care
· Humanistic centered care
· Professionals leading transformations: the strength of professionals to promote transformation
· From health management to ethical leadership
Deadline of submission is on 31 January 2020. For more details and to submit your abstracts, go to https://worldhospitalcongress.org/2020-call-for-papers-and-posters. https://www.ihf-fih.org/ https://www.uch.cat/ Email: Mylene.dayola@ihf-fih.org

Survivors of breast cancer face increased risk of heart disease

, /in /by

Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease. However, some treatment options put these women at greater risk for a number of other health problems. A new study out of Brazil shows that postmenopausal women with breast cancer are at greater risk for developing heart disease.
Cardiovascular disease remains the main cause of death in postmenopausal women, and women treated for breast cancer are at greater risk of developing heart disease than those not diagnosed with breast cancer. These cardiovascular effects may occur more than 5 years after radiation exposure, with the risk persisting for up to 30 years. The goal of the new study was to compare and evaluate risk factors for cardiovascular disease in postmenopausal women who are survivors of breast cancer and women without breast cancer. The researchers found that postmenopausal women who are survivors of breast cancer showed a markedly stronger association with metabolic syndrome, diabetes, atherosclerosis, hypertriglyceridemia, and abdominal obesity, which are major risk factors for cardiovascular disease. The risk of cardiovascular mortality similarly increased to match death rates from the cancer itself.
“Heart disease appears more commonly in women treated for breast cancer because of the toxicities of chemotherapy, radiation therapy, and use of aromatase inhibitors, which lower oestrogen. Heart-healthy lifestyle modifications will decrease both the risk of recurrent breast cancer and the risk of developing heart disease,” says Dr. JoAnn Pinkerton, NAMS executive director. “Women should schedule a cardiology consultation when breast cancer is diagnosed and continue with ongoing follow-up after cancer treatments are completed.”
The North American Menopause Society (NAMS) https://tinyurl.com/up2vyvu

New technique for minimally invasive lung cancer surgery

, /in /by

According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of thoracotomy conversion for VATS/robotic anatomical lung resection. The trial, which included patients in the United States, United Kingdom, and Canada, is the first to evaluate the use of ultrasonic sealing for lobectomy, the most common thoracic surgical procedure.
Technology device trials in thoracic surgery are uncommon, with this study being the first intraoperative device study in more than 20 years. 150 patients planned for VATS/robotic anatomical lung resection in seven centres were enrolled. PA Branches of 7mm or less were sealed and divided with an ultrasonic energy vessel-sealing device. The remainder of the lobectomy was performed according to surgeon preference. A total of 424 PA branches were divided; 239 with the ultrasonic vessel-sealing device, 181 with endostaplers, and 4 with endoscopic clips.
Intraoperative, in-hospital, and 30-day post-operative bleeding and complications were observed. 1.3 percent of the PA branches divided with the ultrasonic vessel-sealing device and 2.2 percent of PA branches divided with endostaplers bled intraoperatively. Among the patients with seal failures, one patient required conversion to thoracotomy for vascular repair in the ultrasonic energy group. There was no postoperative bleeding from divided PA branches with either sealing method. One patient was re-operated for hemothorax from a bleeding bronchial artery. Mean and median length of stay was 4.1 and 3.8 days, respectively. There was no mortality at 30-days.
Preliminary results appear to show that use of an ultrasonic sealing device can decrease the rate of conversion to thoracotomy, resulting in safer and less-invasive procedures.
Lead author, Moishe Liberman, MD, PhD, of the Division of Thoracic Surgery, University of Montréal, explains, "This is an exciting new application of technology to enable minimally invasive lung surgery for the benefit of patients today and in the future. By promoting less invasive procedures, we promote quicker healing and reduce risks, resulting in improved outcomes for patients."
EurekAlert www.eurekalert.org/pub_releases/2019-05/aaft-ntf050419.php

Italian doctors call on world to change perspective on care

, /in , /by

Doctors at the epicentre of the COVID-19 outbreak in Italy have made an urgent call on the rest of the world to change the way they treat pandemic patients. In a paper published in NEJM Catalyst (21 March 2020) they say patient-centred care is no longer feasible in a pandemic and that ‘community-centred’ care should be the new norm.
They say that hospitals might be the main COVID-19 carriers as they are rapidly filled with infected patients.
“This disaster could be averted only by massive deployment of outreach services,” they emphasize.
The doctors (Nacoti M, et al – At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation) who work at Papa Giovanni XXIII Hospital in Bergamo, a brand-new state-of-the-art facility with 48 intensive-care beds, say: “Our own hospital is highly contaminated, and we are far beyond the tipping point: 300 beds out of 900 are occupied by Covid-19 patients. Fully 70% of ICU beds in our hospital are reserved for critically ill Covid-19 patients with a reasonable chance to survive. The situation here is dismal as we operate well below our normal standard of care. Wait times for an intensive care bed are hours long. Older patients are not being resuscitated and die alone without appropriate palliative care, while the family is notified over the phone, often by a well-intentioned, exhausted, and emotionally depleted physician with no prior contact.
“But the situation in the surrounding area is even worse. Most hospitals are overcrowded, nearing collapse while medications, mechanical ventilators, oxygen, and personal protective equipment are not available. Patients lay on floor mattresses. The health care system struggles to deliver regular services — even pregnancy care and child delivery — while cemeteries are overwhelmed, which will create another public health problem.
They say pandemic solutions are required for the entire population, not only for hospitals.

  1. Home care and mobile clinics avoid unnecessary movements and release pressure from hospitals.
  2. Early oxygen therapy, pulse oximeters, and nutrition can be delivered to the homes of mildly ill and convalescent patients, setting up a broad surveillance system with adequate isolation and leveraging innovative telemedicine instruments.

https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0080

MilliporeSigma Response to the COVID-19 Pandemic

, /in , /by

MilliporeSigma, a global life science tools and equipment supplier, is responding to the COVID-19 pandemic with products and solutions for scientists to detect and characterize viruses and to develop vaccines and therapies.
“We are committed to providing researchers with the necessary raw materials, products and services that can aid the global scientific effort to fight this novel virus. We have consolidated this product offering on a dedicated COVID-19 web page https://www.sigmaaldrich.com/covid-19.html, providing a one-stop-shop of approximately 125 products and corresponding information for academic labs and biopharmaceutical companies working to combat the virus, the company said in statement.
“We are not only focused on end-product solutions during this extraordinary time. To provide this level of support for the critical measures underway to contain and treat COVID-19 and to continue providing products that support the development and manufacturing of over-the-counter drugs to complex cell and gene therapies, we are working hard to ensure minimal disruption to our supply chain while remaining committed to the safety of our employees and customers.
“Our 59 manufacturing sites around the world remain operational to ensure that our biopharmaceutical customers have the products and services they need to serve the health needs of a global population.”
The company added that along with this, their top priority remains the safety and well-being of their employees.
“At each of our sites, we have stopped travel, arranged remote working whenever possible and implemented stringent safety measures, such as social distancing and enhanced hygiene protocol. We are leveraging virtual meeting technology to continue collaborating with the global scientific community.”
MilliporeSigma noted: “To aid the ongoing scientific response to COVID-19, we continue to monitor the global situation closely, establishing protocols and guidelines to minimize the impact whenever possible to our sites and supply. We have mobilized a global task force to actively evaluate the overall supply chain of both our products and key raw materials suppliers to mitigate any potential disruption. Leveraging business continuity plans, we remain dedicated to serving our customers in all markets. In China, our suppliers continue to increase their levels of resumed operations and, as shipping lanes in and out of China continue to improve, we are actively monitoring logistic routes and transportation options to fulfil our shipping requirements.
“Throughout all of this, we are following guidance outlined by the WHO, CDC and governments of impacted countries, and our global sites have relevant and approved preparedness plans and are empowered to act per their local scenarios, as necessary.”

Latest issue of International Hospital

April 2024

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.